understanding of the pathogenesis of rheumatoid arthritis (RA), representing a tremendous advance in the management of RA. Such biologic agents produce reliable effects in patients who are resistant to conventional disease-modifying antirheumatic drugs (DMARD). However, these therapies are expensive in comparison with conventional DMARD, and unrestricted use remains unaffordable.
Reactive amyloid A (AA) amyloidosis is a serious and life-threatening systemic complication of RA that arises from chronic, systemic, and longlasting inflammation, with elevat ed levels of serum AA (SAA) protein1 •2-3. SAA is an acute-phase 12.5-kDa apolipoprotein associated with high-density lipoprotein, and is the circulating precursor of amyloid A protein. Amyloid A fibrils are insoluble and can be deposited in systemic organs, including the kidneys, heart, or gastrointestinal (GI) tract, because of the overproduction of SAA under inflammatory conditions2-3,4. The prevalence of reactive AA amyloidosis in patients with RA is unclear, but is no longer considered rare. The frequency of AA amyloidosis associated with RA ranges from 7% to 26%5-6,7-8-9 , although the prevalence of clinically symptomatic amyloidosis is reportedly lower1011. Common clinical signs of reactive AA amyloidosis in patients with RA can be found by careful observation for the onset of proteinuria, kidney insufficiency, or GI tract symptoms, but amyloid deposition itself can be present before clinical signs of AA amyloidosis appear. This subclinical phase might explain the wide variation of disease prevalence.
Treatment with biologies such as anti-TNF and anti-IL-6 receptor antibodies has emerged as a highly effective approach for inducing rapid and sustained clinical remission of RA12,13. Further, these biologies dramatically reduce the systemic inflammatory response. Recently, rheumatologists have focused on therapy with biologies, not only for control of RA disease activity, but also as potential agents for the treatment of reactive AA amyloidosis. These biologies show strong suppression of acute-phase reactants such as SAA. A retrospective study and several case reports have indicated that such agents are effective against AA amyloidosjsi4,i5,16,17 clinical experience with anti-TNF and anti-IL-6 therapy in AA amyloidosis has gradually increased, and reports have revealed short-term effects of these treatments. Reduction of urinary protein or improvement of pathological findings in GI series biopsies has been reported1516. We have demonstrated clinical and pathological improvement in 14 patients with amyloidosis who were treated with biologies17. The prognosis of amyloid patients treated with biologies has not been thoroughly investigated.
Our purpose was to examine the safety and prognosis of anti-TNF and anti-IL-6 therapy in RA patients with reactive AA amyloidosis by following their clinical course in compar ison to patients with AA amyloidosis who did not receive such therapy.
MATERIALS AND METHODS
Patients. One hundred thirty-three patients with an established diagnosis of reactive AA amyloidosis participated in our study between January 1989 and December 2010. Each patient satisfied the 1987 American Rheumatism Association criteria for RA1K. Our study protocol was approved by the Institutional Review Board of Niigata University Hospital, and the subjects gave informed consent to participate.
Patients diagnosed with amyloidosis before 2003 were treated with methotrexate (MTX), cyclophosphamide, and some other immunosuppressant drugs (conservative therapy). After 2003 some patients were given biologies, while others continued with conventional therapy. Indication for the use of biologics was made by following the official Japanese guidelines14. In brief, patients with RA must meet any of the following 3 criteria after treatment with the usual dose of DMARD for 3 months or longer: (1) a 6 tender joints, (2) a 6 swollen joints, and (3) C-rcactivc protein (CRP) i 2.0 mg/dl or erythrocyte sedimentation rate £ 28 mm/h. We recommended that all patients who fulfilled these criteria start biologic therapy. However, some eligible patients chose not to receive biologic therapy because of the high cost. In the nonbiologic group, patients were treated with conventional therapies for amyloidosis, including modulation of dose of steroids or DMARD. In addition, MTX, cyclophos phamide, azathioprinc, and tacrolimus were used to treat arthritis.
Fifty-three patients were treated with biologic agents (biologic group) and 80 patients were not (nonbiologic group). From this study population, 5 patients in whom introduction of hemodialysis (HD) preceded initial admin istration of a biologic agent and 3 patients who started HD at the time of their diagnosis of amyloidosis were excluded from the analysis for HD-frcc survival. Consequently, the number of subjects for the analysis of HD-free survival was 48 in the biologic group and 77 in the nonbiologic group.
Diagnosis of reactive AA amyloidosis. All patients underwent renal biopsy and GI biopsy, which had confirmed the presence of reactive AA amyloidosis before study entry. Upper GI endoscopy was performed on each patient, regardless of the presence or absence of GI symptoms, to obtain biopsy spec imens. Biopsy specimens were obtained from the lesser curvature of the gas tric antrum, the bulbus, and the second portion of the duodenum, regardless of the presence or absence of abnormalities on endoscopy. These biopsy spec imens were fixed in 10% formalin, embedded in paraffin, and sectioned at 5-//m intervals. Sections were stained with H&E and Congo red. Amyloid deposits detected with Congo red showed green birefringence under polariza tion microscopy. These deposits were confirmed to be AA-typc amyloid using 2 techniques: disappearance of Congo red positivity after incubation with potassium permanganate, and immunohistochemical analysis using anti-amy loid A antibody and antiimmunoglobulin light-chain (AL) antibody to exclude AL amyloidosis. Assessment. Clinical data were assessed from the patient records at the time of amyloid detection and administration of biologies. Laboratory indices and clinical evaluations of disease activity included scrum creatinine (Cr), 24-hour proteinuria, and CRP. Other clinical variables examined were total protein, albumin, blood urea nitrogen (BUN), uric acid (UA), and creatinine clearance (Ccr).
Initiation of hemodialysis. Patients with amyloidosis started HD when Ccr levels were < 10 ml/min/1.73 m2, or when Ccr levels were > 10 ml/min/1.73 m2 and pleural effusion, pulmonary congestion, and cardiomegaly were observed.
Statistical analysis. Determination of the onset of the underlying disorder was made retrospectively by review of the patients' charts after the diagnosis of amyloid had been confirmed. The clinical syndrome at presentation was taken as the main reason for the clinician to seek a tissue biopsy to confirm amyloid deposits. All subjects were followed until the end of 2010. The primary endpoint was death and the secondary endpoint was introduction of HD. Of note, no patient received continuous ambulatory peritoneal dialysis. Survival time was counted from the date amyloid was first demonstrated histologically (for the nonbiologic group) or the date when a biologic therapy was started (for the biologic group) up to 72 months, which was the longest followup period observed in the biologic group. For the biologic group, the date of diagnosis of amyloidosis was not used as the starting date for the survival accumulation because all patients were alive from that date until the date of the initial admin istration of a biologic agent. Inclusion of this period would overestimate the survival time of the biologic group, which should be avoided in this study.
Fisher's exact test for dichotomous variables, chi-square test for multicategorical variables, and Student's t test for continuous variables were used to assess the clinical characteristics of patients with amyloidosis. Survival curves were estimated by the Kaplan-Meier technique and statistical differences between 2 curves were analyzed by log-rank test. Cox proportional hazards models were used to assess the effects of biologic therapy on the risk of each endpoint, i.e., models adjusted for sex and age and multivariablc models also adjusted for other possible confounding factors: multivariablc model 1 adjust ed for sex, age, hematocrit, scrum albumin, Cr, and CRP; and multivariablc model 2, which included Ccr in the model instead of Cr. Because the differ ence in the prevalence of severe renal dysfunction may have influenced the dif ference in the prognosis between the 2 groups, subanalyscs were performed excluding subjects with Ccr < 30 ml/min/1.73 m2. All statistical analyses were performed with SPSS v. 13 for Windows (SPSS Inc., Chicago, IL, USA). Tests were 2-tailcd, and differences at p < 0.05 were considered significant.
RESULTS
Clinical features of patients with amyloidosis. One hundred thirty-three patients with AA amyloidosis associated with RA were evaluated. Fifty-three patients were treated with biolog ies (biologic group) and 80 patients were not (nonbiologic group). Table 1 shows the clinical characteristics and labora tory findings in patients. The findings were assessed at the time of diagnosis of amyloidosis in the nonbiologic group and at the time of biologies administration in the biologic group. MTX was administered to more than one-third of the patients in these 2 groups, but the proportions of patients given MTX did not differ significantly between the groups. However, in Japan, we were restricted to use of MTX not more than 8 mg per week: MTX > 8 mg per week was prohibited by the Health, Labor and Welfare Ministry until 2009. Low levels of serum albumin were frequently observed in both groups. Abnormal Cr and elevated CRP values and mild anemia were significantly more frequent in the nonbiologic group. All patients were treated with nonsteroidal antiinflammatory drugs and DMARD. History of treatment with biologic agents. Biologic agents had been administered to all patients in the biologic groups and no patients in the nonbiologic group. The profile of biologic usage is shown in Table 2 . Etanercept was frequently used. Because many of these patients had renal insufficiency, it was difficult to administer MTX. All patients treated with inflix imab received > 6 mg/week, according to drug-use guidelines. Eleven patients were switched to other biologies because of adverse effects or loss of effectiveness. Survival and causes of death. Survival of patients treated or untreated with biologies, determined according to the Kaplan-Meier method, is illustrated in Figure 1 . Of 80 patients in the nonbiologic group, 38 (47.5%) died. Survival was sig- nificantly higher in the biologic group than in the nonbiolog ic group (p = 0.012). In contrast, among the 53 patients in the biologic group, 7 (13.2%) died. Total followup for mortality was 287.6 person-years in the nonbiologic group and 151.3 person-years in the biologic group. The annual rate of mortal ity due to amyloidosis was 13.2% in the nonbiologic group and 4.6% in the biologic group, the rate in the former being about 3 times that in the latter. In the nonbiologic group, 42 patients died between the time of detection of amyloidosis and up to 72 months afterward. In the biologic group, 7 patients died between the time of administration and up to 72 months thereafter. The causes of death are shown in Table 3 . In the Table 1 . Clinical characteristics and laboratory findings of 153 amyloid-positive patients. Baseline data were at diagnosis of amyloidosis for biologic group and at initial administration of biologies for nonbiologic group. Data arc mean (SD) unless otherwise indicated.
Characteristics
Biologic Group, n (W<) nonbiologic group, congestive heart failure, pneumonia, enteritis, and perforative peritonitis were frequent, as report ed9. We gained an impression that treatment with biologies inhibited the progression of congestive heart failure. The inci dence of other causes of death was low.
Cox proportional hazards models for mortality. Although the HR in model 2 was not statistically significant, possibly because of decreased number of valid cases caused by missing Ccr data, the absolute value was comparable with that of the sex-and age-adjusted HR. Even if subjects with Ccr < 30 ml/min/1.73 m2 were excluded from these analyses, HR were not significantly different from those given in Table 4 , although multivariablc HR became statistically insignificant because of the reduced number of subjects analyzed.
Hemodialysis-free survival. Four of 48 patients in the biologic group and 30 of 77 patients in the nonbiologic group started HD. Total followup for mortality was 234.3 person-years in the nonbiologic group and 137.8 person-years in the biologic group. The annual HD initiation rate for patients with amyloi dosis was 12.8% in the former group and 2.9% in the latter, a difference of about 4-fold. The biologic group had a signifi cantly better survival rate (p < 0.001) than the nonbiologic group in terms of the Kaplan-Meier HD-free survival curve ( Figure 2 ). Cox proportional hazards models for initiation of hemodialy sis. Table 5 presents the results of Cox proportional hazards models for initiation of HD. Biologic therapy was significant ly associated with reduced risk of HD initiation in the sex-and age-adjusted model (HR 0.34,95% CI 0.15-0.75, p = 0.007). However, the HR rose to 0.58 (95% CI 0.13-2.47, p = 0.460) and became statistically insignificant in multivariable model 2. When subjects with Ccr < 30 ml/min/1.73 m2 were exclud ed, the HR in multivariable model 2 was elevated further and became close to 1.0 (HR 0.74,95% CI 0.06-8.65, p = 0.814).
DISCUSSION
The frequency of amyloidosis in patients with RA has been reported to range from 5% to 13.3% in cases confirmed by biopsy and from 14% to 26% in cases confirmed by autop sy8,20. We have also reported a 7.1% incidence among patients (100) 42 (100) 49 (100) Figure 2 . Hemodialysis-free survival in patients receiving biologic or nonbiologic therapy, Kaplan-Meier method. HD-frcc survival was significantly higher in the biologic group than the nonbiologic group (p < 0.001).Total fol lowup periods and annual mortality rates were 234.3 person-years and 12.8% in the nonbiologic group, and 137.8 person-years and 2.9% in the biologic group, respectively. Table 5 . Hazard ratio (HR) for hemodialysis according to treatment status of biologies.
H R ( 9 5 % C I ) p S e x -a n d a g e -a d j u s t e d 0 . (biologic group) and 80 who were not (nonbiologic group). Characteristics of these patients arc shown in Table 1 . Renal function in the biologic group was significantly better than that in the nonbiologic group. In Japan, infliximab was intro duced in 2003, etanercept in 2005, and tocilizumab in 2008. Diagnosis of amyloidosis was made earlier in the nonbiologic group than in the biologic group. The time background might have been slightly different between the 2 groups, but the treatment strategies and use of DMARD were the same, except for the use of biologies. Our patients were gradually switched to biologies, as shown in Table 3 . Recently, the European League Against Rheumatism recommendations for the use of biologies were published21. In general, TNF inhibitors are used first, and if this therapy fails, other biolog ies such as abatacept, rituximab, or tocilizumab are consid ered. In Japan, we regularly use TNF inhibitors as a first choice of therapy according to the recommendations. However, some studies have demonstrated a dramatic reduc tion in SAA levels, with subsequent disappearance of the clin ical symptoms of AA amyloidosis, with tocilizumab treat ment15,22. Considering these reports, we have occasionally used tocilizumab as first-line treatment. MTX is now consid ered an "anchor drug" for treatment of RA. Several studies have indicated that MTX use is associated with reduced risk of cardiovascular disease and atherosclerosis, and reduction of mortality due to myocardial infarction and heart failure23,24. Studies have suggested that control of inflammation with MTX may reduce mortality25,26. There was no significant dif ference between our 2 study groups in the frequency of MTX therapy. In Japan, the maximum allowable dosage of MTX was 8 mg per week, until February 2011, but this dosage was not used in amyloidosis patients because of renal damage. For the use of infliximab, more than 6 mg per week of MTX was required. In our study, because most of the amyloidosis patients showed renal dysfunction, the use of infliximab was limited, and this accounted for the better renal function in the biologies group. Recently, reports have described that biolog ies can reduce mortality in patients with RA27,28, but it is dif ficult to prove this effect statistically. Patients with amyloido sis showed a higher mortality rate than patients with RA with out amyloidosis, as we have reported29,30. Thus, we found that biologies reduced mortality in patients receiving them. Our multivariate Cox proportional hazards analysis indicated that the use of biologies was significantly correlated with mortali ty. Renal function is one of the important factors for progno sis. Nevertheless, the magnitude of risk reduction was not sig nificantly changed even after the exclusion of subjects with Ccr < 30 ml/min/1.73 m2.
In contrast, the effects of biologies in terms of initiation of HD were limited. Our Kaplan-Meier survival curve analysis revealed that HD-free survival was significantly improved (Figure 2 ). These patients in the biologic group had been diag nosed as having amyloidosis before receiving the drugs. The annual HD initiation rate in patients with amyloidosis was 14.3% in the nonbiologic group and 6.7% in the biologic group. However, diagnosis of amyloidosis was undertaken earlier in the former group than in the latter. The time back ground might have differed slightly between the groups, but the treatment strategies and DMARD were the same except for the use of biologies, and the guidelines for HD initiation were also the same. The HD initiation rate in the nonbiologic group was about twice that in the biologic group. Our sex-and age-adjusted Cox proportional hazard analysis clearly indicat ed that the use of biologies was correlated with initiation of HD. However, our multivariate Cox proportional hazards analysis indicated that the use of biologies was not predictive of initiation of HD. These results were confirmed by another analysis in which those subjects with Ccr < 30 ml/min/1.73 m2 were excluded. Although this lack of significance in the benefit of biologies shown by multivariate Cox proportional hazard analysis is unclear, several possible explanations can be suggested. Our preliminary data indicated that renal insuf ficiency developed to some extent, which was difficult to ameliorate even when biologies were started (data not shown). We considered that it would be important to introduce biolog ies earlier, before renal damage became apparent. In addition, it was difficult to determine renal function in patients with amyloidosis. A second possibility is that it was difficult to compare survival from the time of diagnosis of amyloidosis, and therefore we chose to assess survival from the time of administration of biologies up to 72 months. The biologic group had a poorer HD-free survival rate than the nonbiolog ic group. A third possibility is that the observation period might have been too short. Considering the Kaplan-Meier HD-free survival curve, if we had continued observations for 1 more year, a significant difference might have emerged.
Causes of death in amyloidosis associated with RA have been well documented30. Our belief was that treatment with biologies inhibited the progression of congestive heart failure. However, we did not use biologies in patients with chronic renal failure. It is possible to consider that biologies remove amyloid deposits from the heart and vessels, and this may inhibit the onset of congestive heart failure. One study demon strated that anti-TNF therapy with etanercept did not have a beneficial effect on the rate of hospitalization death due to chronic heart failure (CHF)31. The authors considered that proinflammatory cytokines did not have a deleterious role in the pathophysiology of CHF. However, none of our patients had CHF upon initiation of biologies.
There have been several attempts to establish an effective protocol for treatment of reactive AA amyloidosis associated with RA, including the use of corticosteroids, immunosup pressants, and biologies such as TNF-a and IL-6 receptor antagonists to control RA disease activity and improve kidney function and overall patient survival32*33. Some reports have suggested that patients with AA amyloidosis have laboratory signs of an inflammatory process, with significantly increased plasma levels of acute-phase proteins such as CRP9r33. Our patients showed high disease activity during the clinical course of RA. Mild azotemia and elevated Cr were frequent, indicating renal insufficiency. Proteinuria was also common in these patients.
We recently reported the effect of anti-TNF therapy for rapid and sustained removal of amyloid deposits in gastric mucosal tissue with amelioration of renal function17. Thus, we speculate that rapid removal of amyloid deposits from renal tissue might have resulted in amelioration of renal function. In patients with amyloidosis, it has not been fully investigated whether biologies reduce mortality. Our data clearly suggest ed that biologic therapy can reduce mortality and risk of HD in these patients. Additionally, we recently reported a program for safe initiation of HD in amyloidosis patients with RA34. Some patients with amyloidosis will progress to endstage renal disease (ESRD) even if they receive biologic therapy. Additionally, the prognosis of amyloidosis patients receiving HD is poor, because of a large number of sudden deaths immediately following HD. Programmed initiation of HD improves the prognosis of patients with ESRD. Use of biologics combined with this program is expected to reduce mor tality, even when these patients might require HD.
We have demonstrated that patients with amyloidosis have a higher mortality rate, but that the use of biologies can reduce mortality, although it may not influence the HD-free survival rate. Therapy with biologic agents is now considered the stan dard method of care for DMARD-resistant patients with RA, and might also become an accepted strategy for amyloidosis patients with RA.
